DOCS vs. SMMT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DOCS and SMMT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DOCS | SMMT |
|---|---|---|
| Company Name | Doximity, Inc. | Summit Therapeutics Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Technology | Biotechnology |
| Market Capitalization | 11.99 billion USD | 19.96 billion USD |
| Exchange | NYSE | NasdaqGM |
| Listing Date | June 24, 2021 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DOCS and SMMT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DOCS | SMMT |
|---|---|---|
| 5-Day Price Return | 9.34% | -9.94% |
| 13-Week Price Return | 4.88% | 7.20% |
| 26-Week Price Return | 9.89% | 23.60% |
| 52-Week Price Return | 83.18% | 138.27% |
| Month-to-Date Return | 8.97% | -2.60% |
| Year-to-Date Return | 19.91% | 43.93% |
| 10-Day Avg. Volume | 2.40M | 2.83M |
| 3-Month Avg. Volume | 2.32M | 4.46M |
| 3-Month Volatility | 49.40% | 97.74% |
| Beta | 1.38 | -1.19 |
Profitability
Return on Equity (TTM)
DOCS
22.38%
Health Care Technology Industry
- Max
- 47.95%
- Q3
- 35.17%
- Median
- 13.74%
- Q1
- 11.05%
- Min
- 11.05%
DOCS’s Return on Equity of 22.38% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
SMMT
-52.22%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
SMMT has a negative Return on Equity of -52.22%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
DOCS
39.13%
Health Care Technology Industry
- Max
- 51.50%
- Q3
- 45.32%
- Median
- 27.34%
- Q1
- 14.21%
- Min
- 14.21%
DOCS’s Net Profit Margin of 39.13% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
SMMT
-9,027.08%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
SMMT has a negative Net Profit Margin of -9,027.08%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
DOCS
39.94%
Health Care Technology Industry
- Max
- 73.15%
- Q3
- 56.55%
- Median
- 26.97%
- Q1
- 22.10%
- Min
- 22.10%
DOCS’s Operating Profit Margin of 39.94% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
SMMT
-8,108.33%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
SMMT has a negative Operating Profit Margin of -8,108.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | DOCS | SMMT |
|---|---|---|
| Return on Equity (TTM) | 22.38% | -52.22% |
| Return on Assets (TTM) | 19.29% | -41.67% |
| Net Profit Margin (TTM) | 39.13% | -9,027.08% |
| Operating Profit Margin (TTM) | 39.94% | -8,108.33% |
| Gross Profit Margin (TTM) | 90.20% | -- |
Financial Strength
Current Ratio (MRQ)
DOCS
6.97
Health Care Technology Industry
- Max
- 7.04
- Q3
- 7.01
- Median
- 4.60
- Q1
- 2.96
- Min
- 0.31
DOCS’s Current Ratio of 6.97 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
SMMT
10.63
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
SMMT’s Current Ratio of 10.63 is in the upper quartile for the Biotechnology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
DOCS
0.00
Health Care Technology Industry
- Max
- 0.06
- Q3
- 0.05
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, DOCS’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
SMMT
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
SMMT’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DOCS
--
Health Care Technology Industry
- Max
- 224.12
- Q3
- 222.84
- Median
- 219.00
- Q1
- 181.50
- Min
- 169.00
Interest Coverage Ratio data for DOCS is currently unavailable.
SMMT
-121.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
SMMT has a negative Interest Coverage Ratio of -121.35. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | DOCS | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 6.97 | 10.63 |
| Quick Ratio (MRQ) | 6.73 | 10.37 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.00 |
| Interest Coverage Ratio (TTM) | -- | -121.35 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 1.12%
- Q3
- 0.62%
- Median
- 0.12%
- Q1
- 0.00%
- Min
- 0.00%
DOCS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SMMT
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 72.22%
- Median
- 42.51%
- Q1
- 0.00%
- Min
- 0.00%
DOCS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SMMT
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | DOCS | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DOCS
53.76
Health Care Technology Industry
- Max
- 343.51
- Q3
- 272.61
- Median
- 54.67
- Q1
- 36.04
- Min
- 31.57
DOCS’s P/E Ratio of 53.76 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SMMT
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for SMMT is currently unavailable.
Price-to-Sales Ratio (TTM)
DOCS
21.04
Health Care Technology Industry
- Max
- 176.90
- Q3
- 98.12
- Median
- 16.38
- Q1
- 4.49
- Min
- 0.00
DOCS’s P/S Ratio of 21.04 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SMMT
21,167.26
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
With a P/S Ratio of 21,167.26, SMMT trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
DOCS
10.06
Health Care Technology Industry
- Max
- 117.60
- Q3
- 90.72
- Median
- 8.09
- Q1
- 3.83
- Min
- 3.06
DOCS’s P/B Ratio of 10.06 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SMMT
41.31
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
At 41.31, SMMT’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | DOCS | SMMT |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 53.76 | -- |
| Price-to-Sales Ratio (TTM) | 21.04 | 21,167.26 |
| Price-to-Book Ratio (MRQ) | 10.06 | 41.31 |
| Price-to-Free Cash Flow Ratio (TTM) | 44.98 | -- |